In reviewing clinical trials [4–21] on EGFR-mutant, brain-metastatic NSCLC and other relevant-topic studies (on advanced patients), multiple EGFR-TKIs have exhibited clinical benefits of enhanced progression-free survival (PFS) and the objective response rate (ORR) as well as a safer profile on these patients over platinum-based chemotherapy [22–26] and radiotherapy (RT) [27]. Here, EGFR is linked to non-small cell lung carcinoma.